Request for Information - Next-Generation COVID-19 Vaccines

The Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), is issuing this Request for Information (RFI) to collect feedback from current and potential biopharmaceutical partners. Information collected from this RFI will serve as continued market research for possible future programs where BARDA would partner with the National Institutes of Allergy and Infectious Diseases (NIAID) as well as other organizations to achieve the pandemic preparedness goals set forth by the U.S. Government (USG). BARDA is issuing this RFI to assist in understanding the advanced developmental landscape of next-generation COVID-19 vaccines. For the purpose of this RFI, next generation vaccines include those with enhanced breadth of protection to variants, improved durability, and those with an enhanced ability to block infection/transmission including mucosal vaccines, relative to currently approved vaccines. BARDA is particularly interested in novel vaccine candidates in clinical trials or capable of entering clinical trials within 9 months.